Agents Intervening Against Delirium in Intensive Care Unit
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Delirium
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Delirium among critically ill patients in the intensive care unit (ICU) is a common condition associated with increased morbidity and mortality. No evidence-based treatment exist of this condition. Haloperidol is the most frequently used agent to treat ICU-related delirium, but according to the avai...
Delirium among critically ill patients in the intensive care unit (ICU) is a common condition associated with increased morbidity and mortality. No evidence-based treatment exist of this condition. Haloperidol is the most frequently used agent to treat ICU-related delirium, but according to the available literature there is no firm evidence of efficacy and safety of this intervention. AID-ICU aims to assess the benefits and harms of haloperidol in adult, critically ill patients with delirium in the ICU.
Tracking Information
- NCT #
- NCT03392376
- Collaborators
- Centre for Research in Intensive Care (CRIC)
- Copenhagen Trial Unit, Center for Clinical Intervention Research
- Scandinavian Critical Care Trials Group
- The Danish Centre of Applied Social Science (VIVE)
- Investigators
- Study Chair: OIe Mathiesen, MD, PhD Zealand University Hospital Study Chair: Anders Perner, MD,PhD Rigshospitalet, Denmark Study Chair: Jørn Wetterslev, MD, PhD Copenhagen Trial Unit, Center for Clinical Intervention Research
Get Well Soon